Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna is projected to see substantial product sales growth, with revenues expected to increase from $1.73 billion in 2025 to $2.15 billion in 2026. The company is enhancing its financial position through a $1.5 billion debt deal which strengthens its balance sheet and provides flexibility to navigate uncertainties and capitalize on future opportunities. Additionally, improvements in manufacturing efficiency are anticipated to restore gross margins from a low of 30% in 2023 to around 50% by 2025, further underpinning the company's profitability outlook.

Bears say

Moderna's stock outlook is negatively impacted by a significant decline in COVID vaccine sales, which dropped from $18 billion in 2022 to $6.7 billion in 2023, coupled with reduced revenue guidance due to waning vaccination rates and increased competition from other RSV vaccines. Additionally, the company's overall revenue growth potential appears limited, as evidenced by the decreased valuation of its COVID-related products from $11.70 billion to $10.50 billion, reflecting an ongoing transition from pandemic to endemic conditions. Furthermore, issues such as low expectations for EU sales negotiations and slow progress in their clinical pipeline outside of respiratory vaccines contribute to the prevailing uncertainties surrounding Moderna's financial future.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.